Researchers have identified a protein, TPPP3, that enables ovarian cancer cells to resist chemotherapy, offering a potential new target to restore the effectiveness of standard treatments. By blocking this protein, laboratory models demonstrated that cancer cells regained sensitivity to cisplatin, a widely used chemotherapy drug. The findings, published in the journal Cell Reports, suggest that shifting focus from DNA damage to the physical internal structure of cancer cells could provide a more durable approach to preventing disease recurrence.
Cisplatin and related drugs like carboplatin have long been used in treating ovarian and other cancers, primarily for their ability to induce DNA damage in malignant cells. However, this study reveals that these chemotherapy agents also work by disrupting microtubules—the essential internal scaffolding that allows cells to survive. When these structures are compromised, the cancer cell typically dies.
The research team, which includes scientists from Michigan State University, the National Cancer Institute, and the National Institutes of Health, discovered that cancer cells often develop resistance by stabilizing this internal scaffolding. At the center of this defense mechanism is the protein tubulin polymerization promoting protein 3 (TPPP3). According to lead researcher Sachi Horibata, an assistant professor in the Precision Health Program and pharmacology and toxicology department at the Michigan State University College of Human Medicine, TPPP3 acts as a protective shield for the cancer cell.
How Cancer Cells Reprogram Defenses
The study highlights a process scientists refer to as the “tubulin code,” where cancer cells undergo structural changes to stabilize their microtubules under the stress of chemotherapy. While traditional treatments focus on repairing or inducing DNA damage, this new evidence suggests that cancer cells are capable of physically reinforcing their internal architecture to withstand drug exposure. Patients with lower levels of TPPP3 lived longer and responded better to treatment, reinforcing the protein’s role as a key factor in chemo resistance.
“We have learned how cancer cells adapt to chemotherapy by altering their internal structure,” says Horibata. “This enables them to survive and ultimately resist treatment.” By removing TPPP3 in laboratory settings, researchers were able to weaken the cell’s defenses, allowing chemotherapy to function as intended. This discovery helps explain why some patients are told they are cancer-free, only to see the disease return.
Future Clinical Applications
The research team is now working to translate these laboratory findings into clinical strategies. One primary goal is the development of therapeutic agents designed to target and inhibit TPPP3. Researchers are also investigating whether TPPP3 levels can serve as a biomarker to identify which patients are at a risk of developing chemotherapy resistance. By identifying these patients early, clinicians might eventually be able to personalize treatment plans.
Beyond ovarian cancer, the researchers are exploring whether this mechanism plays a role in other types of cancer. Furthermore, because microtubules are fundamental to the function of healthy cells, this research may provide critical insights into the biological basis of common chemotherapy side effects, such as nerve damage, hair loss, and hearing loss. Understanding how the “tubulin code” is manipulated could lead to treatments that are more effective and more durable.
Collaborative Research Efforts
The study involved a broad collaboration across several major scientific institutions. Contributors included researchers from the National Institute of Neurological Disorders and Stroke, the Center for Cancer Research, and the Center for Biomedical Informatics & Information Technology at the National Cancer Institute. The project was supported by funding from Michigan State University, the Japan Society for the Promotion of Science, the Intramural Research Program of the National Cancer Institute, the National Institute of Neurological Disorders and Stroke, the National Heart and Lung Institute, and the Intramural Research Program of the National Institutes of Health.
As the scientific community continues to analyze these findings, the next phase of research will focus on how this mechanism affects current chemotherapy combinations. This work marks a shift toward a more nuanced understanding of cancer cell biology, moving beyond genetic mutations to address the physical survival strategies of tumors.
Readers interested in the latest developments in oncology research can follow updates from the National Cancer Institute for official guidance on clinical trials and emerging cancer therapies. Join the conversation below to share your thoughts on this shift toward targeting tumor structural proteins.
Worth a look